

Kate E Lines

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2761065/publications.pdf>

Version: 2024-02-01

31
papers

521
citations

687220

13
h-index

677027

22
g-index

32
all docs

32
docs citations

32
times ranked

794
citing authors

#	ARTICLE	IF	CITATIONS
1	The Bartter-Gitelman Spectrum: 50-Year Follow-up With Revision of Diagnosis After Whole-Genome Sequencing. <i>Journal of the Endocrine Society</i> , 2022, 6, .	0.1	7
2	miR-3156-5p is downregulated in serum of MEN1 patients and regulates expression of MORF4L2. <i>Endocrine-Related Cancer</i> , 2022, 29, 557-568.	1.6	5
3	Multiple Endocrine Neoplasia Type 1: Latest Insights. <i>Endocrine Reviews</i> , 2021, 42, 133-170.	8.9	85
4	CTNNB1-Mutant Aldosterone-Producing Adenomas With Somatic Mutations of GNA11/GNAQ Have Distinct Phenotype and Genotype. <i>Journal of the Endocrine Society</i> , 2021, 5, A65-A66.	0.1	0
5	Multiple endocrine neoplasia type 1 in children and adolescents: Clinical features and treatment outcomes. <i>Surgery</i> , 2021, , .	1.0	10
6	PTH Infusion for Seizures in Autosomal Dominant Hypocalcemia Type 1. <i>New England Journal of Medicine</i> , 2021, 385, 189-191.	13.9	11
7	Somatic mutations of GNA11 and GNAQ in CTNNB1-mutant aldosterone-producing adenomas presenting in puberty, pregnancy or menopause. <i>Nature Genetics</i> , 2021, 53, 1360-1372.	9.4	37
8	The bromodomain inhibitor JQ1+ reduces calcium-sensing receptor activity in pituitary cell lines. <i>Journal of Molecular Endocrinology</i> , 2021, 67, 83-94.	1.1	1
9	Activating Mutations of the G-protein Subunit β 1 Interdomain Interface Cause Autosomal Dominant Hypocalcemia Type 2. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 952-963.	1.8	6
10	Whole genome sequence analysis identifies a PAX2 mutation to establish a correct diagnosis for a syndromic form of hyperuricemia. <i>American Journal of Medical Genetics, Part A</i> , 2020, 182, 2521-2528.	0.7	3
11	Clinical MEN-1 Among a Large Cohort of Patients With Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2271-e2281.	1.8	19
12	Multiple Endocrine Neoplasia Type 1 (MEN1) 5'UTR Deletion, in MEN1 Family, Decreases Menin Expression. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 100-109.	3.1	10
13	Multiple Endocrine Neoplasia Type 1 (MEN1) Phenocopy Due to a Cell Cycle Division 73 (<i>CDC73</i>) Variant. <i>Journal of the Endocrine Society</i> , 2020, 4, bvaa142.	0.1	5
14	Effects of epigenetic pathway inhibitors on corticotroph tumour AtT20 cells. <i>Endocrine-Related Cancer</i> , 2020, 27, 163-174.	1.6	5
15	Preclinical drug studies in MEN1-related neuroendocrine neoplasms (MEN1-NENs). <i>Endocrine-Related Cancer</i> , 2020, 27, R345-R355.	1.6	5
16	Genetic background influences tumour development in heterozygous Men1 knockout mice. <i>Endocrine Connections</i> , 2020, 9, 426-437.	0.8	5
17	Two Synchronous Pituitary Adenomas Causing Cushing Disease and Acromegaly. <i>AACE Clinical Case Reports</i> , 2019, 5, e276-e281.	0.4	1
18	Epigenetic dysregulation in pituitary tumors. <i>International Journal of Endocrine Oncology</i> , 2019, 6, IJE19.	0.4	3

#	ARTICLE	IF	CITATIONS
19	Association of prolactin receptor (<i>PRLR</i>) variants with prolactinomas. <i>Human Molecular Genetics</i> , 2019, 28, 1023-1037.	1.4	24
20	MON-335 Phenocopy of Multiple Endocrine Neoplasia Type 1 (MEN1) Due to a Germline Cell Division Cycle 73 (CDC73) Variant. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.1	1
21	miR-15a/miR-16-1 expression inversely correlates with cyclin D1 levels in Men1 pituitary NETs. <i>Journal of Endocrinology</i> , 2019, 240, 41-50.	1.2	12
22	Current and emerging therapies for PNETs in patients with or without MEN1. <i>Nature Reviews Endocrinology</i> , 2018, 14, 216-227.	4.3	46
23	Molecular Genetic Studies of Pancreatic Neuroendocrine Tumors. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 525-548.	1.2	17
24	A MEN1 pancreatic neuroendocrine tumour mouse model under temporal control. <i>Endocrine Connections</i> , 2017, 6, 232-242.	0.8	17
25	Mice deleted for cell division cycle 73 gene develop parathyroid and uterine tumours: model for the hyperparathyroidism-jaw tumour syndrome. <i>Oncogene</i> , 2017, 36, 4025-4036.	2.6	28
26	miR-135b- and miR-146b-dependent silencing of calcium-sensing receptor expression in colorectal tumors. <i>International Journal of Cancer</i> , 2016, 138, 137-145.	2.3	32
27	Pasireotide Therapy of Multiple Endocrine Neoplasia Type 1â€“Associated Neuroendocrine Tumors in Female Mice Deleted for an Men1 Allele Improves Survival and Reduces Tumor Progression. <i>Endocrinology</i> , 2016, 157, 1789-1798.	1.4	26
28	Animal models of pituitary neoplasia. <i>Molecular and Cellular Endocrinology</i> , 2016, 421, 68-81.	1.6	20
29	Molecular genetic advances in pituitary tumor development. <i>Expert Review of Endocrinology and Metabolism</i> , 2015, 10, 35-53.	1.2	5
30	S100P is a metastasis-associated gene that facilitates transendothelial migration of pancreatic cancer cells. <i>Clinical and Experimental Metastasis</i> , 2013, 30, 251-264.	1.7	41
31	S100P-Binding Protein, S100PBP, Mediates Adhesion through Regulation of Cathepsin Z in Pancreatic Cancer Cells. <i>American Journal of Pathology</i> , 2012, 180, 1485-1494.	1.9	34